{"product_id":"global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2016-2023","title":"Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2016-2023","description":"\u003cp\u003eGlobal Cancer Monoclonal Antibody Partnering Terms and Agreements 2016-2023\u003cbr\u003e\nThe Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2016-2023 report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eTrends in cancer monoclonal antibody partnering deals\u003cbr\u003e\nMost active companies in cancer monoclonal antibody partnering\u003cbr\u003e\nDisclosed headlines, upfronts, milestones and royalties by stage of development\u003cbr\u003e\nCancer monoclonal antibody partnering contract documents\u003cbr\u003e\nTop cancer monoclonal antibody deals by value\u003c\/p\u003e\n\n\u003cp\u003eThis report provides details of the latest cancer monoclonal antibody agreements announced in the healthcare sectors.\u003c\/p\u003e\n\n\u003cp\u003eThis report provides details of the latest antibody agreements announced in the healthcare sectors, covering:\u003c\/p\u003e\n\n\u003cp\u003eMonoclonal antibodies\u003cbr\u003e\nMurine mAb\u003cbr\u003e\nChimeric mAb\u003cbr\u003e\nHumanized mAb\u003cbr\u003e\nHuman aAb\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains a comprehensive listing of all cancer monoclonal antibody partnering deals announced since Jan 2016, including financial terms where available, including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides a review of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value, signed by big pharma, most active cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R\u0026amp;D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, a comprehensive appendix is provided organized by cancer monoclonal antibody partnering company A-Z, deal type definitions and cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2016.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.\u003c\/p\u003e\n\n\u003cp\u003eKey benefits\u003c\/p\u003e\n\n\u003cp\u003eGlobal Cancer Monoclonal Antibody Partnering Terms \u0026amp; Agreements provides the reader with the following key benefits:\u003cbr\u003e\nIn-depth understanding of cancer monoclonal antibody deal trends since 2016\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nComprehensive access to over 600 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies\u003cbr\u003e\nIdentify most active companies in cancer monoclonal antibody partnering\u003cbr\u003e\nInsight into the terms included in a cancer monoclonal antibody agreement\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals           \u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003cbr\u003e\nSpot the emerging companies in the cancer monoclonal antibody area\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Cancer Monoclonal Antibody Partnering Terms \u0026amp; Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eCancer Monoclonal Antibody Partnering Terms \u0026amp; Agreements includes:\u003cbr\u003e\nTrends in cancer monoclonal antibody dealmaking in the biopharma industry since 2016\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nAccess to over 600 cancer monoclonal antibody deal records\u003cbr\u003e\nThe leading cancer monoclonal antibody deals by value since 2016\u003c\/p\u003e\n\n\u003cp\u003eIn Cancer Monoclonal Antibody Partnering Terms \u0026amp; Agreements, the available deals are listed by:\u003cbr\u003e\nCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nDeal component type\u003cbr\u003e\nSpecific oncology therapy target\u003cbr\u003e\nMonoclonal antibody type\u003c\/p\u003e\n\n\u003cp\u003eEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe Cancer Monoclonal Antibody Partnering Terms \u0026amp; Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:\u003cbr\u003e\nWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 400 Pages \/ MCW16229728","offer_id":47646996103474,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2016-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}